KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacific Biosciences Of California (PACB) Asset Writedowns and Impairment (2022 - 2025)

Historic Asset Writedowns and Impairment for Pacific Biosciences Of California (PACB) over the last 4 years, with Q1 2025 value amounting to $15.0 million.

  • Pacific Biosciences Of California's Asset Writedowns and Impairment rose 49990000.0% to $15.0 million in Q1 2025 from the same period last year, while for Sep 2025 it was $106.3 million, marking a year-over-year increase of 726.97%. This contributed to the annual value of $184.5 million for FY2024, which is 164319.73% up from last year.
  • According to the latest figures from Q1 2025, Pacific Biosciences Of California's Asset Writedowns and Impairment is $15.0 million, which was up 49990000.0% from $91.3 million recorded in Q4 2024.
  • Pacific Biosciences Of California's Asset Writedowns and Impairment's 5-year high stood at $93.2 million during Q2 2024, with a 5-year trough of $3000.0 in Q1 2024.
  • Its 4-year average for Asset Writedowns and Impairment is $18.0 million, with a median of $2.4 million in 2022.
  • In the last 5 years, Pacific Biosciences Of California's Asset Writedowns and Impairment tumbled by 9991.48% in 2024 and then skyrocketed by 49990000.0% in 2025.
  • Pacific Biosciences Of California's Asset Writedowns and Impairment (Quarter) stood at $3.4 million in 2022, then surged by 75.39% to $5.9 million in 2023, then soared by 1449.3% to $91.3 million in 2024, then tumbled by 83.57% to $15.0 million in 2025.
  • Its Asset Writedowns and Impairment was $15.0 million in Q1 2025, compared to $91.3 million in Q4 2024 and $93.2 million in Q2 2024.